GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
AssigneeChildren's Hospital & Research Center at Oakland
InventorsDan M. Granoff, Victor Chen-Hsi Hou
Life of this patent
Estimating the term…
Abstract
The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.
Claims15
A composition comprising:
- isolated antigenic vesicles prepared from a Neisseria meningitidis (N. meningitidis) genetically modified to disrupt production of the endogenous GNA1870 polypeptide so that the endogenous GNA1870 is not present at detectable levels in the isolated antigenic vesicles and to overexpress at least one full length meningococcal GNA1870 polypeptide at a level sufficient to provide for production of the isolated antigenic vesicles that, when administered to a mammalian subject elicit anti-meningococcal GNA1870 polypeptide antibodies,
- wherein the overexpressed GNA1870 polypeptide is a meningococcal variant 1, a variant 2 GNA1870 polypeptide, or a variant 3 GNA1870 polypeptide heterologous to the N. meningitidis,
- wherein the isolated antigenic vesicles are outer membrane vesicles (OMVs), microvesicles (MVs), or a mixture of the OMVs and the MVs, and
- wherein the N. meningitidis is genetically modified to provide for decreased toxic activity of its lipid A relative to its parental unmodified N. meningitidis;
- and
- a pharmaceutically acceptable carrier.
A Neisseria meningitidis (N. meningitidis) genetically modified to disrupt production of the endogenous GNA1870 polypeptide so that the endogenous GNA1870 is not present at detectable levels in antigenic vesicles prepared from the N. meningitidis and to overexpress at least one full length meningococcal GNA1870 polypeptide at a level sufficient to provide for production of the isolated antigenic vesicles that, when administered to a mammalian subject, elicit anti-meningococcal GNA1870 polypeptide antibodies, wherein the overexpressed GNA1870 polypeptide is a meningococcal variant 1, a variant 2, or a variant 3 GNA1870 polypeptide heterologous to the N. meningitidis, and wherein the antigenic vesicles are outer membrane vesicle (OMV), microvesicle (MVs), or a mixture of the OMVs and the MVs.
Dependencies are inferred from the claim text.